Introduction
============

Liver disease has become one of the most important cause of morbidity and mortality in HIV-infected individuals ([@ref-41]). While hepatitis B or C co-infections remain the most important cause of liver damage, liver related mortality also affects those infected only with HIV ([@ref-2]). Long term antiretroviral and non-antiretroviral medications, HIV induced long term inflammation, metabolic complications and direct cytopathic effects may also contribute to the pathogenesis of liver fibrosis (LF) ([@ref-34]). An increasing number of papers have been published on fibrosis in HIV/hepatitis virus co-infected patients ([@ref-3]; [@ref-5]; [@ref-7]; [@ref-9]; [@ref-11]; [@ref-17]; [@ref-18]; [@ref-19]; [@ref-20]; [@ref-21]; [@ref-23]; [@ref-25]; [@ref-28]; [@ref-36]; [@ref-40]) but only a few studies have appeared on the analysis of data obtained from HIV mono-infected individuals ([@ref-1]; [@ref-8]; [@ref-14]; [@ref-22]; [@ref-33]; [@ref-38]).

With the availability of noninvasive fibrosis determinations, such as liver stiffness (LS) measurements with transient elastography, aspartate aminotransferase (AST)-to-platelet ratio index (APRI) and the FIB-4 score, cross-sectional and prospective studies to evaluate prevalence and incidence of LF in HIV-infected individuals have become easier. These tests were demonstrated to be acceptable in predicting the absence of fibrosis or mild fibrosis (LF \< 2 METAVIR score) and the presence of advanced fibrosis (LF \> 3 METAVIR score) ([@ref-12]). Cross-sectional studies in HIV mono-infected patients reported high rates (11--47%) of significant LF suggesting that HIV itself may contribute independently to liver damage ([@ref-34]). Ongoing LF is not always accompanied by elevated liver enzymes. Thus, the diagnosis of LF and the prevention of progression to liver cirrhosis are important challenges. As a result, adequate monitoring strategies of liver disease are clearly needed to optimize care of HIV-infected individuals.

To date, only a few studies using LS measurements have examined the prevalence and potential risk factors for hepatic fibrosis among HIV mono-infected patients. Using different cutoff values resulted in a wide range in prevalence estimates ([@ref-14]; [@ref-27]). Pre-defined cutoffs adopted from the HIV/HCV-co-infected population may lead to an underestimation of the number of HIV mono-infected patients with clinically significant fibrosis as these cutoffs were determined for a population in which ongoing fibrosis is triggered by HCV co-infection ([@ref-14]). To overcome this limitation, our aim was to use a continuous scale of LS values without any cutoff to identify significant predictors of LS in a cross-sectional study.

Materials & Methods
===================

Study population
----------------

The investigation was performed in accordance with the Helsinki Declaration and was approved by the Institutional Review Board of St. István and St. László Hospital, Budapest, Hungary (approval number: 34/EB/2013). Written informed consent was taken from all study participants. The present cross-sectional study is an analysis of data collected for a previous study, with methodology already described ([@ref-39]). Individuals older than 18 years of age were enrolled after providing their written informed consent. Pregnant women and patients with unreliable transient elastography measurement were excluded. Patients with known HCV or HBV infection or anti-HBc positivity, known other risk factors of liver diseases, or significant daily alcohol intake (\>50 g/day) were excluded from the analysis.

From March 1, 2014 to October 30, 2014 all HIV-infected patients who attended the outpatient clinic at the HIV Center, St. István and St. László Hospital (Budapest, Hungary) were invited to participate in the study (*n* = 756). Liver stiffness measurements were performed on 139 patients. Out of this cohort 101 individuals were eligible for the final analysis ([Fig. 1](#fig-1){ref-type="fig"}). The mode of transmission of HIV was reported to be sexual intercourse in all patients. The baseline study population characteristics are summarized in [Table 1](#table-1){ref-type="table"}.

![Recruitment flow of the study participants.](peerj-05-2867-g001){#fig-1}
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###### Study population (*n* = 101) characteristics.

Due to missing values descriptive statistics of BMI (body mass index) and serum triglyceride values are derived from 100 individuals, serum cholesterol, the length of known HIV positivity and hypertension from 99 individuals.
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  Parameter                      Mean (Median) ± SD (IQR) \[Min--Max\]
  ------------------------------ ------------------------------------------
  CD4 %                          27.6 (29) ± 9 (11) \[1--46\]
  CD8%                           45.1 (44) ± 12.7 (17) \[20--78\]
  CD4/8 ratio                    0.7 (0.6) ± 0.4 (0.5) \[0--1.8\]
  Age (years)                    44.6 (42.4) ± 11.4 (13.4) \[24.4--71.3\]
  BMI (kg/m^2^)                  25 (24.8) ± 3.2 (3.3) \[18.1--37.8\]
  Serum triglyceride (mmol/L)    2.8 (2) ± 2.5 (2.4) \[0--13.1\]
  Serum cholesterol (mmol/L)     5.4 (5.4) ± 1.5 (1.8) \[0--10.9\]
  Known HIV positivity (years)   9.2 (7) ± 6.4 (9) \[0.8--25\]
  Liver Stiffness (kPa)          5.7 (5.1) ± 3.3 (1.7) \[3--34.3\]
  CAP (dB/m)                     250.6 (239) ± 56.4 (74) \[165--385\]
                                 *N* (%)
  ART ever taken                 92 (91.1)
  Darunavir                      20 (19.8%)
  Atanazavir                     7 (6.9%)
  Raltegravir                    8 (7.9%)
  Etravirine                     9 (8.9%)
  Nevirapine                     22 (21.8%)
  Efavirenz                      27 (26.7%)
  Tenofovir                      38 (37.6%)
  Abacavir                       13 (12.9%)
  Zidovudine                     39 (38.6%)
  Lamivudine                     89 (88.1%)
  Lopinavir                      26 (25.7%)
  Gender (female)                3 (3%)
  Diabetes                       11 (10.9%)
  Hypertension                   21 (21.2%)
  Lipodystrophy                  12 (11.9%)

**Notes.**

CAPcontrolled attenuation parameterARTantiretroviral therapy

Transient elastography
----------------------

Transient elastography examination was performed by experienced investigators at the Hepatology Center of Buda, Budapest, Hungary, using a FibroScan 502 equipment (Fibroscan , EchoSens™, Paris, France). Measurements were performed using M probe on the right lobe of the liver, through intercostal spaces according to instructions by the manufacturer. Examinations with 10 successful shots and an interquartile range (IQR) for LSs less than 30% of the median value were considered as reliable. Details of the technical background and the examination procedure have been previously described elsewhere ([@ref-35]). We used a continuous scale of LS values in our statistical analyses to avoid information loss emerging from categorization of the variable. However, to describe the patient population we adopted the cutoff for significant LF of 7.2 kPa and 5.3 kPa, and 14.6 kPa to define the presence of cirrhosis ([@ref-14]; [@ref-40]).

Interview and clinical assessment
---------------------------------

Clinical parameters were collected on the day of transient elastography examination. Recorded data were as follows: age, sex, body mass index (BMI), facial lipodystrophy assessment (defined by the presence deeper cheek atrophy), smoking, alcohol intake, drug use, type of antiretroviral medication (ARV), co-medications, comorbidities, and date of HIV diagnosis. Biochemical and immunological parameters, blood count, CD4 and CD8 count were collected at the visit when the informed consent was obtained (\<4 weeks before the LS measurement).

Statistical analysis
--------------------

The primary outcome variable was liver stiffness. The univariate association with categorical variables was assessed by a two independent sample Mann--Whitney *U* test (i.e., Wilcoxon rank-sum test). The univariate correlation with continuous variables was assessed using the Pearson and Kendall-*τ* rank-correlation coefficient. Visualization was performed with scattergrams indicating best fitting linear curve and LOWESS-smoother. Holm correction was performed to counteract problems related to multiple comparisons.

Multivariate analysis was performed using Bayesian Model Averaging (BMA). Results are shown as posterior effect---or inclusion---probability (PEP), and expected value and standard deviation of the posterior distribution for each covariate ([@ref-16]; [@ref-31]). Best models are illustrated visually by depicting the variables included in them.

Calculations were performed using R ([@ref-29]) with library BMA ([@ref-30]). Data and script are available as [Supplemental Information S1](#supp-1){ref-type="supplementary-material"} and [S2](#supp-2){ref-type="supplementary-material"}.

Results
=======

LS ranged from 3.0 kPa to 34.3 kPa with a median value of 5.1 kPa (IQR 1.7). According to the HIV/HCV co-infection LS cutoffs, significant LF defined as LS \> 7.2 kPa was detectable in 10/101 (9.9%) individuals. Presence of cirrhosis (LS \> 14.6 kPa) was observed in two (1.98%) participants. Applying the cutoff (5.3 kPa) from a healthy population, significant fibrosis was detected in 45/101 (44.55%) patients.

Significant Pearson and Kendall correlation was found between LS and controlled attenuation parameter (CAP) value (*p* = 0.022985; *p* = 0.0000162), age (*p* = 0.003794; *p* = 0.006593) and BMI (*p* = 0.010303; *p* = 0.000146).With regard to categorical variables, significant association could be identified with hypertension (*p* = 0.04548) but not with ARVs. After correction due to multiple testing, only association with LS and BMI (*p* = 0.0048114) and LS and CAP (*p* = 0.0005496) remained significant. Associations of LS and different continuous and categorical variables are presented in [Tables 2](#table-2){ref-type="table"}--[3](#table-3){ref-type="table"} and [Figs. 2A](#fig-2){ref-type="fig"}--[2I](#fig-2){ref-type="fig"}.

10.7717/peerj.2867/table-2

###### Univariate analysis: associations between liver stiffness and continuous variables.

The *p*-value pertains to the null hypothesis of no correlation; *p*-values are unadjusted.
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  Variable                       Pearson    Kendall               
  ------------------------------ ---------- ---------- ---------- -----------
  CD4%                           −0.087     0.386973   0.008555   0.901708
  CD8%                           0.075447   0.453335   −0.01846   0.789103
  CD4/8 ratio                    −0.10605   0.291208   −0.00341   0.960177
  Age (years)                    0.285574   0.003794   0.185478   0.006593
  BMI (kg/m^2^)                  0.255489   0.010303   0.26108    0.000146
  Triglyceride (mmol/L)          0.026998   0.78975    0.079497   0.250808
  Cholesterol (mmol/L)           0.028166   0.781974   0.059661   0.3915
  Known HIV positivity (years)   0.147292   0.145703   0.126008   0.073529
  CAP (dB/m)                     0.226115   0.022985   0.295207   0.0000162

**Notes.**

BMIbody mass indexCAPcontrolled attenuation parameter
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###### Univariate analysis: associations between the liver stiffness and categorical variables.

Liver stiffness (LS) values are presented in mean (median) ± SD (IQR) \[minimum--maximum\] format. *p*-value pertains to the null hypothesis of stochastic equivalence of the two populations (presence/absence).
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  Categorical variable   LS in the presence of variable                  LS in the absence of variable                 *p*
  ---------------------- ----------------------------------------------- --------------------------------------------- ---------
  ART ever taken         *n* = 92, 5.7 (5.2) ± 3.4 (1.8) \[3.1--34.3\]   *n* = 9, 4.9 (4.3) ± 1.9 (1.9) \[3--9.3\]     0.13281
  Darunavir              *n* = 20, 5.6 (5.3) ± 1.7 (2) \[3.5--10.2\]     *n* = 81, 5.7 (5) ± 3.6 (1.7) \[3--34.3\]     0.41051
  Atanazavir             *n* = 7, 5.3 (5.2) ± 1.3 (1.6) \[3.6--7.3\]     *n* = 94, 5.7 (5) ± 3.4 (1.7) \[3--34.3\]     0.84091
  Raltegravir            *n* = 8, 6.2 (5) ± 3.7 (0.7) \[3.9--15.3\]      *n* = 93, 5.6 (5.2) ± 3.3 (1.9) \[3--34.3\]   0.91481
  Etravirine             *n* = 9, 4.9 (4.8) ± 1 (1.9) \[3.6--6.3\]       *n* = 92, 5.7 (5.1) ± 3.5 (1.8) \[3--34.3\]   0.42414
  Nevirapine             *n* = 22, 5.3 (5.3) ± 1.1 (1.8) \[3.6--7.4\]    *n* = 79, 5.8 (5) ± 3.7 (1.7) \[3--34.3\]     0.85302
  Efavirenz              *n* = 27, 5.4 (5.3) ± 1.4 (2.3) \[3.1--8.8\]    *n* = 74, 5.8 (5) ± 3.8 (1.7) \[3--34.3\]     0.59088
  Tenofovir              *n* = 38, 6.3 (5.3) ± 5.1 (2.1) \[3.1--34.3\]   *n* = 63, 5.3 (5) ± 1.3 (1.7) \[3--10.2\]     0.54861
  Abacavir               *n* = 13, 5.6 (5.8) ± 1.8 (2) \[3.6--10.2\]     *n* = 88, 5.7 (5) ± 3.5 (1.8) \[3--34.3\]     0.81937
  Zidovudine             *n* = 39, 5.5 (4.9) ± 2 (1.7) \[3.7--15.3\]     *n* = 62, 5.8 (5.2) ± 4 (1.9) \[3--34.3\]     0.94157
  Lamivudine             *n* = 89, 5.7 (5.1) ± 3.5 (1.8) \[3.1--34.3\]   *n* = 12, 5.1 (4.4) ± 1.8 (1.9) \[3--9.3\]    0.22107
  Lopinavir              *n* = 26, 6.7 (5) ± 6.1 (1.8) \[3.6--34.3\]     *n* = 75, 5.3 (5.1) ± 1.4 (1.7) \[3--10.2\]   0.65209
  Gender (female)        *n* = 3, 4.7 (4.9) ± 0.6 (0.5) \[4--5.1\]       *n* = 98, 5.7 (5.2) ± 3.4 (1.9) \[3--34.3\]   0.44681
  Diabetes               *n* = 11, 7 (6.3) ± 3.3 (2.6) \[3.9--15.3\]     *n* = 90, 5.5 (5) ± 3.3 (1.6) \[3--34.3\]     0.06365
  Hypertension           *n* = 21, 6.1 (5.4) ± 2.4 (1.5) \[4--15.3\]     *n* = 78, 5.5 (4.9) ± 3.6 (1.8) \[3--34.3\]   0.04548
  Lipodystrophy          *n* = 12, 5.3 (5) ± 1 (1.6) \[4--6.9\]          *n* = 89, 5.7 (5.1) ± 3.5 (1.7) \[3--34.3\]   0.82133

**Notes.**

ARTantiretroviral therapy

![Correlations between continuous variables and liver stiffness.\
The black line shows the best-fitting linear curve, the red line shows the LOWESS-smoother. (A--I) refer to the correlation between liver stiffness value and the corresponding variable.](peerj-05-2867-g002){#fig-2}

Next, we performed a multivariate analysis to investigate the effect of these parameters on LS. Results of BMA are given in [Table 4](#table-4){ref-type="table"}. We identified a very high support for age (PEP: 84.5%), moderate for BMI (PEP: 49.3%), CD4/8 ratio (PEP: 44.2%) and lipodystrophy (PEP: 44.0%). On the other hand, for all remaining variables, the model rather provided evidence against their effect. [Figure 3](#fig-3){ref-type="fig"} shows the best models graphically. These results overall suggest that age and BMI have a positive association with LS, while CD4/8 ratio and lipodystrophy are negatively associated.
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###### Results of Bayesian Model Averaging (BMA).
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  Variables                      PEP (%)   EV            SD
  ------------------------------ --------- ------------- -----------
  Intercept                      100.0     −0.5095082    3.712.817
  CD4%                           17.1      −0.0130202    0.034393
  CD8%                           12.9      0.0061567     0.020026
  Age (years)                    84.5      0.0827192     0.048982
  BMI (kg/m^2^)                  49.3      0.1213562     0.147793
  CD4/8 ratio                    44.2      −0.9654844    1.276.960
  Triglyceride (mmol/L)          1.6       −0.0005448    0.018470
  Cholesterol (mmol/L)           1.6       −0.0011508    0.030622
  Sex                            2.2       −0.0277561    0.342417
  Diabetes                       3.3       0.0331575     0.282103
  Hypertension                   1.5       0.0001101     0.106425
  Lipodystrophy                  44.0      −11.266.415   1.508.412
  Known HIV positivity (years)   2.4       0.0004474     0.015563
  Darunavir                      2.0       −0.0092738    0.147354
  Atanazavir                     1.9       −0.0139616    0.231754
  Raltegravir                    1.5       0.0012294     0.162407
  Etravirine                     8.5       −0.1378151    0.583234
  Nevirapine                     2.9       −0.0197049    0.183840
  Efavirenz                      2.2       −0.0102161    0.134693
  Tenofovir                      14.0      0.1519821     0.461496
  Abacavir                       1.6       0.0022876     0.135247
  Zidovudine                     10.5      −0.1116331    0.406437
  Lamivudine                     1.5       0.0027499     0.132358
  Lopinavir                      26.7      0.3950730     0.778517
  CAP (dB/m)                     8.9       0.0009069     0.003627

**Notes.**

PEPPosterior effect probabilityEVexpected value of the posterior distribution of the parameterSDstandard deviationCAPControlled attenuation parameterARTAntiretroviral therapy

![Models selected by BMA (Bayesian Model Averaging).\
Red color displays negative, blue displays positive variable estimate (uncolored variables were not included in the model). On the *x*-axis, models are listed in the order of decreasing posterior model probability.](peerj-05-2867-g003){#fig-3}

It is worth noting that even the best model has only 2.4% posterior probability (even the cumulative posterior probability for the 10 best models is only 15.6%). The best model includes age (*β* = 0.10 \[0.039--0.16\], *p* = 0.00174) and CD4/8 ratio (*β* =  − 2.2 \[−4.1---0.28\], *p* = 0.02501), but these results should be interpreted with caution in the light of the substantial model uncertainty.

Discussion
==========

To our knowledge, only a few studies assessing liver stiffness in HIV-infected patients without HBV or HCV infection have been published so far. In these publications a wide range of prevalence for abnormal LS values were identified ([@ref-14]; [@ref-22]; [@ref-27]; [@ref-34]). Using these applied cutoff values we had a similarly wide prevalence range (9.9--44.55%). These diverse results clearly underline the importance of identifying better cutoff values in HIV mono-infected patients. The most reliable method for this would be to perform liver biopsy in a large unselected HIV mono-infected population and to compare its results with those of transient elastography. Nevertheless, to our knowledge, no such study has been carried out. The discrepancies in cutoff values might lead to unreliable estimation of the rate and grade of LF. Therefore, we used a continuous scale of LS for our correlation and regression analyses to avoid uncertainty arising from using a pre-defined abnormal values as a cutoff point.

BMA revealed age as the most important predictor of LS. Age is a well-known risk factor for LF in non-alcoholic fatty liver disease (NAFLD) and HCV-infected patients ([@ref-6]). However, data about age-related fibrosis in the HIV mono-infected population are scarce ([@ref-34]). To date, only a few descriptive studies identified significant association with age and LF in this patient population ([@ref-4]; [@ref-14]; [@ref-27]). Ageing has multiple effects on the liver, making it more vulnerable to fibrogenetic factors. The exact mechanism, however, remains unknown. The decreased regenerative capacity, microbial translocation and HIV-induced immunologic dysfunction as well as chronic inflammation may play non-mutually exclusive roles ([@ref-6]). This result was also in line with our other finding, the identified remarkable negative association between LS and CD4/8 ratio. The low CD4/8 ratio is an accepted marker of HIV-induced immune dysregulation ([@ref-37]). Therefore, this observation could reflect on the role of HIV-induced immune dysregulation in the development LF. In this population, persisting abnormally low CD4/8 ratio is associated with impaired gut mucosal immunity ([@ref-37]). Destruction of the mucosal barrier leading to microbial translocation could be a driving force of LF. In a recent study, a marker of microbial translocation, elevated sCD14 levels were associated with increased LS in HIV mono-infected individuals ([@ref-32]). In HCV-infected patients, the CD4/8 ratio as a contributing factor to LF has also been considered ([@ref-10]). Furthermore, CD4 cells can stimulate anti-fibrotic natural killer cell activity, therefore, loss and impaired activity of CD4 cells may contribute to the progression of LF ([@ref-34]). Data suggesting HIV-induced effects on the pathogenesis of fibrosis generation has been described mainly in patients with HIV/HCV co-infection ([@ref-34]) but the mechanism has still not been exactly determined. In context of the ageing HIV population, a better understanding of how ageing interacts with HIV-induced immunologic and metabolic changes will have paramount importance in reducing the burden of liver diseases ([@ref-6]).

CAP value, quantifying hepatic steatosis showed significant correlation with LS in the univariate analysis. Remarkably, NAFLD is the most frequent cause of liver damage in this population ([@ref-33]). However, other studies found no association with LS and CAP ([@ref-24]; [@ref-26]). Nonetheless, multivariate analyses rather provided evidence against the effect of CAP on LS.

The correlation between BMI and LS portrays a similar profile. BMI, the most important predictor of CAP value in the HIV-infected population ([@ref-24]; [@ref-26]; [@ref-39]) showed significant association with LS in the univariate analysis. This association remained considerable according to the result of the BMA. This suggests, that obesity may have an independent unfavorable effect on LF even in the absence of -with CAP detectable- hepatic steatosis.

No significant association was observed between LS and ARVs. These results underline the importance of antiretroviral treatment, however, other studies have raised questions about the role of older ARVs in LF development. A cumulative exposure to boosted protease inhibitors (PI) was identified as a significant independent negative predictor of LF ([@ref-14]). A possible explanation of this result could be, that a longer cumulative boosted PI exposure may reflect on a better long-term control of viral load and a lower grade of immune dysregulation. Since body-fat composition abnormalities are associated with PI exposure ([@ref-13]), the identified negative association with the presence of facial lipodystrophy in our study may further support this theory. However, prospective, controlled trials are clearly warranted to clarify the role of PI therapy in the development of LF. Associations with didanosine and stavudine with hepatic fibrosis were previously described ([@ref-1]; [@ref-4]; [@ref-27]). In our investigated population, the number of dideoxynucleoside exposed patients was negligible (*n* = 2); therefore, we did not include these ARVs in our analysis.

The observed outlier value in one participant (LS = 34.3 kPa) refers to an advanced liver disease of unknown origin. Similarly, other observational studies in the HIV mono-infected population also identified individuals with high grade fibrosis and even with cryptogenic cirrhosis ([@ref-22]; [@ref-27]). Recently, cirrhosis was identified in 5.2% percent of the HIV mono-infected patients (defined as LS \> 10.3 kPa) compared to the 0.6% of the uninfected control group ([@ref-22]). These data underscore the importance of identifying other underlying liver diseases and improving the understanding of pathomechanism.

It is worth contrasting these result with those obtained using traditional linear regression (without variable selection). At 5%, age (*p* = 0.0415), BMI (*p* = 0.0204), presence of lipodystrophy (*p* = 0.0131), history of taking zidovudine (*p* = 0.0442) and lopinavir (*p* = 0.0173) were significant. However while this model has an apparent *R*^2^ of 36%, its realistic---overfitting-optimism corrected---*R*^2^ is practically zero (obtained through bootstrap validation). Thus, regularization was applied---with the penalty parameter selected by Hurvich and Tsai's corrected AIC---which resulted in a realistic model, however, it had no significant variable at all ([@ref-15]). This experiment clearly illustrates the problems of modelling with so limited sample size, and the possible advantages of BMA. In particular for small datasets the effect of model uncertainty can be substantial---this is disrespected in the framework of traditional regression modelling. Variable selection is often employed; however, when it is non-blinded to the outcome, it leads to models that are biased in virtually all of their parameters. For small sample sizes, the sound alternatives - such as regularization - might lead to results that are clinically not meaningful. BMA is a relevant alternative, which avoids these issues by explicitly considering many models.

Our study has considerable limitations. The observational nature and low patient number being probably the most important ones. The number of excluded patients with significant alcohol intake has also to be dealt with caution. Since alcohol consumption was assessed by self-reporting, there is a possibility that not all affected individuals were identified. Moreover, the distance between the HIV center, where screening occurred and the hepatology center where transient elastography measurement took place was the main reason potential participants refused participation in the study. This could lead to selection bias, since low-compliance patients could be underrepresented in the study population.

Conclusions
===========

In conclusion, using previously described cutoff values we identified a high prevalence of hepatic fibrosis in HIV mono-infected patients. Our findings shed light on the relevance of HIV-induced immune dysregulation and overweight in the ageing HIV-infected population. The negative association between LS and the presence of lipodystrophy may reflect on the protective effect of prolonged exposure to antiretroviral therapy.

Fueled by the ongoing silent epidemic of obesity, the burden of liver diseases in individuals living with HIV shifts away from viral hepatitis coinfections to the NAFLD spectrum. A better understanding of factors leading to fibrosis will be the cornerstone of reduction in liver-related disease burden in the HIV-infected population. Nonetheless, further controlled studies are warranted to clarify causal relations.
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###### Supplemental Information 1. Dataset file

Each row contains values obtained from one participant. Columns representing variables according to labels in the Supplemental File 2 (SI2).

###### 

Click here for additional data file.
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###### Statistical Analysis

R Script of the performed statistical analysis, including descriptive statistics, plotting, Bayesian Model Averaging and comparative penalized regression.

###### 

Click here for additional data file.
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